{
    "clinical_study": {
        "@rank": "141405", 
        "arm_group": [
            {
                "arm_group_label": "Corn and safflower oil", 
                "arm_group_type": "Placebo Comparator", 
                "description": "The oil (60 g/d/3000 kcal) is given in two daily fruit beverage for 4 weeks."
            }, 
            {
                "arm_group_label": "High Oleic Canola Oil and DHA (HOCO-DHA)", 
                "arm_group_type": "Active Comparator", 
                "description": "The oil (60 g/d/3000 kcal) is given in two daily fruit beverage for 4 weeks."
            }, 
            {
                "arm_group_label": "Barley Beta-glucan", 
                "arm_group_type": "Active Comparator", 
                "description": "The Barley beta-glucan (3 g/d/3000 kcal) is given in two daily fruit beverage for 4 weeks."
            }, 
            {
                "arm_group_label": "HOCO-DHA and Barley beta-glucan", 
                "arm_group_type": "Active Comparator", 
                "description": "The oil and beta-glucan (60g and 3g/d/3000 kcal, respectively) is given in two daily fruit beverage for 4 weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to examine the effects of consumption of a novel supplement\n      beverage consisting of Canola Oil, Fibre and DHA, containing the most effective food\n      bioactives, including n-3 fatty acid enriched dietary oil high in monounsaturated fatty\n      acids (MUFAs) and soluble dietary fibre, aiming at the management of heart disease risk\n      factors in people with metabolic syndrome and to test its efficacy and safety in humans."
        }, 
        "brief_title": "Canola Oil, Fibre and DHA Enhanced Clinical Trial", 
        "condition": "Metabolic Syndrome", 
        "condition_browse": {
            "mesh_term": "Metabolic Syndrome X"
        }, 
        "detailed_description": {
            "textblock": "The proposed study is a randomized, double-blind, crossover trial, it will be conducted at\n      the Richardson Centre for Functional Food and Nutraceuticals (RCFFN), University of\n      Manitoba. The study design will consist of 4 phases with 28 days per phase, each phase will\n      be separate by 4-week washout periods. Participants will consume a controlled\n      weight-maintaining diet (35% energy from fat, 50% carbohydrate, 15% protein) supplemented\n      with the following novel beverages: (a) control beverage containing corn and safflower oil\n      comprised largely of saturated fat with substantial levels of n-6 linoleic acid, common to\n      current North American intakes, (b) beverage containing high oleic canola oil and\n      docosahexaenoic acid (HOCO-DHA), (c) beverage containing high molecular weight barley\n      B-glucan, (d) beverage containing combination of HOCO-DHA and high molecular weight barley\n      \u03b2-glucan. Treatments will be isocalorically incorporated into fruit beverage made with fruit\n      juice and consumed in equal parts at breakfast and supper."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  BMI\u226525 Kg/m2\n\n          -  Waist circumference \u226594 cm (males) or \u226580 cm (females)\n\n        Meet at least two of the following:\n\n          -  Triglycerides \u22651.7 mmol/L\n\n          -  High density lipoprotein (HDL) cholesterol <1 mmol/L (males) or <1.3 mmol/L (females)\n\n          -  Low density lipoprotein (LDL) cholesterol \u22652.7 mmol/L\n\n          -  Fasting glucose \u22655.6 mmol/L\n\n        Exclusion Criteria:\n\n          -  Consuming lipid lowering medications\n\n          -  Consuming nutritional supplements\n\n          -  Disease or disorder that could interfere with absorption\n\n          -  Smokers\n\n          -  Hypertension \u2265150 mmHg (systolic) and/or \u2265100 mmHg (diastolic)\n\n          -  Planning to become pregnant\n\n          -  Consume >1 alcoholic drink/day\n\n          -  Medication within a month prior to screening"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "35", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 12, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02091583", 
            "org_study_id": "B2014:029"
        }, 
        "intervention": [
            {
                "arm_group_label": "Corn and safflower oil", 
                "intervention_name": "Corn and safflower oil", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": [
                    "High Oleic Canola Oil and DHA (HOCO-DHA)", 
                    "HOCO-DHA and Barley beta-glucan"
                ], 
                "intervention_name": "High Oleic Canola Oil and DHA (HOCO-DHA)", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": [
                    "Barley Beta-glucan", 
                    "HOCO-DHA and Barley beta-glucan"
                ], 
                "intervention_name": "Barley beta-glucan", 
                "intervention_type": "Dietary Supplement"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Metabolic syndrome", 
            "Cardiovascular disease", 
            "High Oleic Canola Oil", 
            "DHA", 
            "\u03b2-glucan", 
            "Barley", 
            "Cholesterol", 
            "Lipoproteins", 
            "Lipids", 
            "Inflammation", 
            "Glucose", 
            "Insulin", 
            "Satiety", 
            "Body composition", 
            "Blood pressure"
        ], 
        "lastchanged_date": "April 9, 2014", 
        "location": {
            "contact": {
                "email": "peter_jones@umanitoba.ca", 
                "last_name": "Peter Jones, PhD", 
                "phone": "204-474-8883"
            }, 
            "facility": {
                "address": {
                    "city": "Winnipeg", 
                    "country": "Canada", 
                    "state": "Manitoba", 
                    "zip": "R3T 2N2"
                }, 
                "name": "Richardson Centre for Functional Foods and Nutraceuticals"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "4", 
        "official_title": "Developing and Evaluating a Novel Supplement Beverage, Consisting of Canola Oil, Fibre and DHA, Aiming at the Management of CVD Risk in a Population With Metabolic Syndrome", 
        "overall_contact": {
            "email": "Peter.Jones@umanitoba.ca", 
            "last_name": "Peter JH Jones, PhD", 
            "phone": "2044748883"
        }, 
        "overall_contact_backup": {
            "email": "vanu_ramprasath@umanitoba.ca", 
            "last_name": "Vanu Ramprasath, PhD", 
            "phone": "2044749989"
        }, 
        "overall_official": [
            {
                "affiliation": "Richardson Centre for Functional Foods and Nutraceuticals, University of Manitoba", 
                "last_name": "Peter JH Jones, PhD", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "Agriculture and Agri-Food Canada", 
                "last_name": "Nancy Ames, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Richardson Centre for Functional Foods and Nutraceuticals, University of Manitoba", 
                "last_name": "Vanu R Ramprasath, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Agriculture and Agri-Food Canada", 
                "last_name": "Sijo Joseph, PhD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Canada: Public Health Agency of Canada", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Change in 10-year Framingham CVD risk will be assessed using the multivariable  Framingham risk equation.", 
            "measure": "Change in 10-year Framingham CVD risk score", 
            "safety_issue": "No", 
            "time_frame": "The 10-year Framingham CVD risk score will be calculated for each participant at the end of each four 4-week treatment phases over a period of seven months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02091583"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Lipid profile will be determined using the automated enzymatic methods. Subfractions and particle size of LDL-C and HDL-C will be determined by LipoprintR system.", 
                "measure": "Change in blood lipid profile (TC, TG, LDL-C, HDL-C)", 
                "safety_issue": "No", 
                "time_frame": "Blood samples will be collected at the start and end of each of the four 4-week treatment phases over a period of seven months"
            }, 
            {
                "description": "Determination of inflammatory markers and cytokines will be measured by commercially available ELISA kits.", 
                "measure": "Change in inflammatory markers", 
                "safety_issue": "No", 
                "time_frame": "Blood samples will be collected at the start and end of each of the four 4-week treatment phases over a period of seven months"
            }, 
            {
                "description": "Participants will be asked to consume 13C-cholesterol and deuterium oxide (D2O) at the end of each phase. On day 23, fasting blood samples will be obtained (0h), prior to oral administration of a 75mg of 13C-cholesterol mixed in 5g of margarine and spread on half English muffin. Fasting samples will be obtained over the following 96 hours on day 24 (24h), day 25 (48h), day 26 (72h) and day 27 (96h) to measure cholesterol absorption. In addition, on day 27 a fasting baseline blood sample is taken prior to administration of an oral dose of D2O as tracer to measure fractional cholesterol synthesis. Fasting blood samples will be obtained 24 h following the tracer dose on day 28.", 
                "measure": "Cholesterol absorption and synthesis rate", 
                "safety_issue": "No", 
                "time_frame": "Fasting blood samples will be collected during the last 6 days of the four 4-week treatment phases over a period of seven months"
            }, 
            {
                "description": "Changes in body composition will be assessed using dual-energy X-ray absorptiometry (DXA) scans. In addition, body weight, waist and hip circumferences will be measured.", 
                "measure": "Change in body composition", 
                "safety_issue": "No", 
                "time_frame": "Measurements will be done at the beginning and end of each of the four 4-week treatment phases over a period of seven months"
            }, 
            {
                "description": "Blood pressure data (change in both systolic and diastolic) was taken 4 times at 2-minutes intervals. The last 3 measurements will be averaged.", 
                "measure": "Blood Pressure", 
                "safety_issue": "No", 
                "time_frame": "Measurements will be done at the beginning and end of each of the four 4-week treatment phases over a period of seven months"
            }, 
            {
                "description": "Insulin concentrations will be determined using ELISA kits. Glucose concentrations will be determined using a finger-prick blood glucose monitor. In addition, glucose response to breakfast will be assess before and at 15, 30, 45, 60, 90 and 120 minutes following the initiation of breakfast.", 
                "measure": "Fasting insulin and glucose and insulin homeostasis modelling assessment (HOMA)", 
                "safety_issue": "No", 
                "time_frame": "Measurements will be done at the beginning and end of each of the four 4-week treatment phases over a period of seven months"
            }, 
            {
                "description": "Participants will be given 30 minutes to consume the full portion of their prescribed treatment. At 60 minutes after treatment participants will be instructed to eat until they reached a point of comfortable satisfaction. Food intake and level of comfortably full will be assessed by questionnaire. In addition, a visual analogue scale (VAS) questionnaire will be used to measure motivation to eat before and after an all you can eat meal.", 
                "measure": "Satiety", 
                "safety_issue": "No", 
                "time_frame": "Assessment will be done at the end of the four 4-week treatment phases over a period of seven months"
            }
        ], 
        "source": "University of Manitoba", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Canadian Institutes of Health Research  (CIHR)", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Agriculture and Agri-Food Canada", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "University of Manitoba", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}